Professor of Therapeutic Radiology at Yale School of Medicine, and Scientific Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. “We are honored to have Merck recognize the ...

Modifi Biosciences, Inc., has announced that the company has been acquired by Merck, known as MSD outside of the United ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

professor of Therapeutic Radiology at Yale School of Medicine, and scientific director of the Yale Brain Tumor Center at Smilow Cancer Hospital, in a press release. “We are honored to have Merck ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...